drugset / Trial / NCT00721045
A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure
RandomizedFactorialSingle-blindTreatment
Summary
This is a dose-ranging clinical study to evaluate the feasibility, safety, and tolerability of 3 different doses of immunoselected, culture expanded, nucleated, allogeneic MPCs in subjects who have cardiomyopathy of both ischemic and idiopathic etiology.
Timeline
- Start
- 2008-08
- Primary completion
- 2011-06
- Completion
- 2013-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mesenchymal Precursor Cells (MPCs) | Cell therapy | 2.5e+07 cells | Other |
| Comparator | Mesenchymal Precursor Cells (MPCs) | Cell therapy | 7.5e+07 cells | Other |
| Comparator | Mesenchymal Precursor Cells (MPCs) | Cell therapy | 1.5e+08 cells | Other |